A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BioNTech SE
BioNTech SE
BioNTech SE
Boehringer Ingelheim
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Novartis
Janssen Research & Development, LLC
National Cancer Institute (NCI)
7 Hills Pharma, LLC
National Cancer Institute (NCI)
Bristol-Myers Squibb
Parabilis Medicines, Inc.
Genmab
National Institutes of Health Clinical Center (CC)
Verastem, Inc.
Novartis
Revolution Medicines, Inc.
Ipsen
Recurv Pharma Inc
University of Chicago
Revolution Medicines, Inc.
858 Therapeutics, Inc.
Radiopharm Theranostics, Ltd
Blue Earth Diagnostics
National Institutes of Health Clinical Center (CC)
Erasca, Inc.
Eisai Inc.
Tianjin Medical University Cancer Institute and Hospital
GlaxoSmithKline
Alentis Therapeutics AG
Artios Pharma Ltd
Novartis
Frontier Medicines Corporation
Roswell Park Cancer Institute
Elicio Therapeutics
Massachusetts General Hospital
PMV Pharmaceuticals, Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Betta Pharmaceuticals Co., Ltd.
HonorHealth Research Institute
M.D. Anderson Cancer Center
Akeso
National Cancer Institute (NCI)
Neonc Technologies, Inc.
Icahn School of Medicine at Mount Sinai
Institut du Cancer de Montpellier - Val d'Aurelle
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sichuan Enray Pharmaceutical Sciences Company
Children's Oncology Group
A2 Biotherapeutics Inc.